Comparative Self-collection for Cervical Cancer Screening Pivotal Study

The purpose of this pivotal study is to generate the clinical evidence necessary to support FDA marketing authorization for the Mia device. Specifically, the study will evaluate the diagnostic agreement of Mia-collected self-samples against the standard of care clinician-collected method for primary hrHPV detection, confirm device safety, demonstrate that end users across a diverse population can use the device safely and effectively as directed.

Inclusion criteria

Group 1: General Population Group

• Participants are 25 to 65 years of age and willing to provide informed consent.
• Participants have an intact cervix.

Group 2: Enriched Population Group

• Participants are 25 to 65 years of age and willing to provide informed consent.
• Participants have an intact cervix.
• One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.

Exclusion criteria

Apply to all groups:

• Impaired decision-making capacity or inability to provide informed consent.
• History of partial or total hysterectomy, including removal of the cervix.
• Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy).
• Current pregnancy (based on self-reporting).
• Active menstruation at time of specimen collection.
• Vaginal bleeding within 48 hours.
• Have had sex or used tampons, creams, or other vaginal products in the last 48 hours.
• Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study.
• Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.